Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06881992 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
A Phase 3 study of Tumor Hyperinsulinism (Tumor HI), sponsored by Rezolute.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
- 13
- Study locations
NCT06881992: Recruiting Phase 3 study of Tumor Hyperinsulinism (Tumor HI), sponsored by Rezolute.
NCT06881992 is a Phase 3 study of Tumor Hyperinsulinism (Tumor HI) that is actively recruiting participants, run by Rezolute. The registered enrollment target is 16 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). The trial reports 13 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06881992, a Phase 3 study of Tumor Hyperinsulinism (Tumor HI), is actively recruiting participants, sponsored by Rezolute.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
- 13
- Study locations
Study Summary
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Conditions Studied
Interventions
- DRUG Ersodetug
Study Locations (13)
Illinois
- Investigative Site - Chicago
Maryland
- Investigative Site - Bethesda
Massachusetts
- Investigative Site - Boston
Minnesota
- Investigative Site - Rochester
New York
- Investigative Site - New York
Ohio
- Investigative Site - Canton
Oregon
- Investigative Site - Portland
Texas
- Investigative Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-04-16 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
What NCT06881992 shows while recruiting
NCT06881992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Tumor Hyperinsulinism (Tumor HI) appearing as the primary indexed condition, and to 1 intervention - of which Ersodetug is the first listed.
NCT06881992 lists 13 locations in 13 states (Illinois, Maryland, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06881992 about?
NCT06881992 is a clinical study titled "A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism". The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
What is the current status of trial NCT06881992?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2025-04-16. Estimated completion is 2027-09.
What conditions does trial NCT06881992 study?
This clinical trial studies the following conditions: Tumor Hyperinsulinism (Tumor HI).
What interventions are being tested in trial NCT06881992?
The interventions under investigation include: Ersodetug (DRUG).
Who is sponsoring clinical trial NCT06881992?
This trial is sponsored by Rezolute, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06881992 being conducted?
This trial has 13 study locations across Illinois, Maryland, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06881992's enrollment target sits among peer trials
16 1975th of 2000 higher than 24 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI